نتایج جستجو برای: high dose cytarabine
تعداد نتایج: 2292508 فیلتر نتایج به سال:
Over the past 2 decades the advent of new therapeutic strategies has led to remarkable progress in the treatment of acute myeloid leukemia (Aml) [1]; however, some serious side effects of treatment may be clinically apparent [2]. An 8-year-old boy was diagnosed as Aml and started on Aml-BFm 2004 therapy in August 2009. There were no important side effects observed until the initiation of hAm bl...
Following reports of childhood acute myeloid leukemia (AML) showing that patients with t(9; 11)(p22; q23) have a better prognosis than those with translocations between 11q23 and other chromosomes, we compared response to therapy and survival of 24 adult de novo AML patients with t(9; 11) with those of 23 patients with other 11q23 translocations [t(11q23)]. Apart from a higher proportion of Fre...
The standard therapy for acute myelogenous leukemia (AML) continues to be based on cytarabine (ara-C, DepoCyt, Enzon), typically in combination with anthracyclines such as idarubicin (Idamycin, Pfizer) or daunorubicin (Cerubidine, Bedford). Although 60% to 70% of patients achieve complete remissions (CRs), most patients relapse and ultimately die of the disease or of associated complications. T...
We are writing to clarify the interpretation of results contained within a paper by Giles et al.1 In their abstract, the authors state, “The [complete remission] CR rate was significantly higher for the laromustine/[high-dose cytarabine] HDAC group (35% vs 19%, P .005). However, the 30-day mortality rate and median progression-free survival were significantly worse in this group compared with H...
Seventeen patients with therapy-related myelodysplastic syndrome (t-MDS) or therapy-related acute nonlymphocytic leukemia (t-ANLL) were treated with single-agent high-dose cytarabine (HDAC; 1 to 3 g/m2 every 12 hours for 12 doses). The initial neoplasm was still present in eight patients when t-MDS/t-ANLL developed. Fifteen of the 16 patients with chromosomal abnormalities in bone marrow cells ...
Mnk kinases regulate the phosphorylation and activation of the eukaryotic initiation factor 4E (eIF4E), a protein that plays key roles in the initiation of messenger RNA translation and whose activity is critical for various cellular functions. eIF4E is deregulated in acute myeloid leukemia (AML), and its aberrant activity contributes to leukemogenesis. We determined whether cercosporamide, an ...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید